ArticleThe Journal of biological chemistry2017
Activation of D2 Dopamine Receptors in CD133+ve Cancer Stem Cells in Non-small Cell Lung Carcinoma Inhibits Proliferation, Clonogenic Ability, and Invasiveness of These Cells.
Article in The Journal of biological chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 53 citations in OpenAlex.
- DRD1 downregulation contributes to mechanical stretch-induced lung endothelial barrier dysfunction.Theranostics · 2021Trial
- miR-34a-5p-mediated inhibition on the KRT5/DSP axis blunts cancer stem cell properties and cisplatin resistance in non-small cell lung cancer.Discover oncology · 2026Article
- Melatonin inhibits malignant biological behaviors in carboplatin-resistant ovarian cancer cells: elucidating the potential molecular mechanisms.Molecular biology reports · 2026Article
- The stem cell atlas of lung adenocarcinoma: A stemness blueprint for prognosis and immunotherapy success.Translational oncology · 2026Article
- A prognostic nomogram for overall survival in patients with driver-gene-negative lung adenocarcinoma and its biological basis.Discover oncology · 2026Article
- Neurotransmitters and Immunity: Molecular Mechanisms, Biological Functions, Diseases, and Potential Therapeutic Targets.MedComm · 2025Review
- Neurotransmitter Regulatory Networks: A New Perspective on Cancer Therapy.Biomolecules · 2025Review
- Cancer and neurotransmitter receptors.Chinese medical journal · 2025Review
- The molecular features of lung cancer stem cells in dedifferentiation process-driven epigenetic alterations.The Journal of biological chemistry · 2024Review
- Therapeutic strategies for colorectal cancer: antitumor efficacy of dopamine D2 receptor antagonists.Toxicological research · 2024Review
- The role of the ALKBH5 RNA demethylase in invasive breast cancer.Discover oncology · 2024Article
- Extracellular vesicles in non-small cell lung cancer stemness and clinical applications.Frontiers in immunology · 2024Review
- Comprehensive assessment of base excision repair (BER)-related lncRNAs as prognostic and functional biomarkers in lung adenocarcinoma: implications for personalized therapeutics and immunomodulation.Journal of cancer research and clinical oncology · 2023Article
- Antiangiogenic Effect of Dopamine and Dopaminergic Agonists as an Adjuvant Therapeutic Option in the Treatment of Cancer, Endometriosis, and Osteoarthritis.International journal of molecular sciences · 2023Review
- The tumor-nerve circuit in breast cancer.Cancer metastasis reviews · 2023Review
- The multifaceted roles of matrix metalloproteinases in lung cancer.Frontiers in oncology · 2023Review
- Understanding the role of dopamine in cancer: past, present and future.Carcinogenesis · 2022Review
- Lung Cancer Stem Cells and Their Clinical Implications.Cold Spring Harbor perspectives in medicine · 2022Review
- The Inhibitory Effect of Selected DCells · 2022Article
- Impact of Cancer Stem Cells and Cancer Stem Cell-Driven Drug Resiliency in Lung Tumor: Options in Sight.Cancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
Lung carcinoma is the leading cause of cancer-related death worldwide, and among this cancer, non-small cell lung carcinoma (NSCLC) comprises the majority of cases. Furthermore, recurrence and metastasis of NSCLC correlate well with CD133+ve tumor cells, a small population of tumor cells that have been designated as cancer stem cells (CSC). We have demonstrated for the first time high expression of D
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.